Elevated fibroblast growth factor 23 (FGF-23) is independently associated with increased inflammatory markers in chronic kidney disease. Lanthanum carbonate (LaCa) reduces FGF-23. We studied the effects of LaCa on inflammatory profile of hemodialysis patients, and the relationship with changes in FGF-23. This prospective study was performed under habitual clinical practice conditions. Twenty-six hemodialysis patients with serum phosphate> 5 mg/dl receiving calcium-based phosphate binders were switched to LaCa. Ten patients with phosphate :5 5 mg/dl under calcium-based phosphate binders were enrolled as a control group for comparison. Serum calcium, phosphorus, calcium-phosphate product (CaxP), intact parathyroid hormone and the inflammatory profile [including serum high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-a (TNF-a), interleukin (IL)-6 and IL-10, as well as mRNA expression levels ofTNF-n and IL-6 in peripheral blood mononuclear cells] were analyzed. Serum FGF-23 significantly decreased in patients switched to LaCa (P < 0.01), with a concomitant reduction in serum hsCRP (-10.9%, P < 0.01), TNF-a (-6.7%, P < 0.05) and IL-6 (-8.1 %, P < 0.01). mRNA expression levels ofTNF-a and IL-6 in PBMC also decreased by 7.8% (P < 0.05) and 10.3% (P < 0.01), respectively. Multivariate regression analysis demonstrated that variations in FGF-23 were the only independent determinant of the changes in serum and mRNA expression levels of inflammatory parameters. In conclusion, LaCa posses anti-inflammatory actions, which are significant and independently associated with the reduction of FGF-23. FGF-23 may regulate inflammatory cytokine gene expression at the transcriptional level. Whether these effects have influence on clinical outcomes warrants consideration.
.
The decline in renal function is accompanied by a progressive elevation of the bone-derived phosphaturic hormone fibroblast growth factor (FGF-23) (6) , which starts in early stages of CKD, reaching the highest concentrations in patients with end-stage renal disease (ESRD) (7) . Elevated levels of FGF-23 have been associated with deleterious cardiovascular effects, including vascular calcification, left ventricular hypertrophy and increased mortality (8) (9) (10) . This relationship seems to be independent of phosphate levels, suggesting the existence of unknown mechanisms that mediate this action. A recent study has shown that higher FGF-23 concentrations are independently associated with increased levels of inflammatory markers and with significantly greater odds of severe inflammation (11).
The use of phosphate binders is a common requirement in CKD patients. These compounds have been related to diverse pleiotropic actions, including anti-inflammatory effects (4, 12) . More recently, it has been reported that non-calcium phosphate binders are also able to decrease circulating FGF-23 (13) (14) (15) . However, whether the action of these phosphate binders upon inflammatory status may be related to their capacity to reduce FGF-23 levels remains unknown.
The objective of this study is to evaluate prospectively the effect ofthe non-calcium phosphate binder lanthanum carbonate (LaCa) on the serum and gene expression profile of inflamatory parameters in HD patients. Serum FGF-23 concentrations were measured before and after LaCa administration to test the hypothesis that changes in FGF-23 levels are associated with simultaneous variations in inflammatory variables.
MATERIALS AND METHODS

Study design and participants
This was an independent, prospective study in conditions of habitual clinical practice, carried out in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines and applicable regulations. The protocol was approved by the institutional ethics committee and patients provided informed consent.
The primary endpoint was to evaluate the effects of LaCa on the serum inflammatory profile of HD patients. Secondary objectives were (I) to study the gene expression levels of the inflammatory cytokines tumor necrosis factor-a (TNF-a) and interleukin (IL)-6 in peripheral blood mononuclear cells (PBMC), (2) to analyze the effect of LaCa administration on the serum concentrations of FGF-23, and (3) to evaluate the relationship between changes in FGF-23 and variations in inflammatory parameters.
Stable patients on maintenance HD (4 h/session, 3 sessions/week, no dialysis filter reuse) for more than six months were included. Eligibility criteria were: patients of either sex, age over 18 years, with serum concentration of 25-hydroxyvitamin D higher than 20 ng/ml, receiving treatment with a calcium-based phosphate binder, and no vitamin D or calcimimetics therapy. Exclusion criteria included treatment with a non-calcium phosphate binder, severe gastrointestinal disease, current smoking habit, alcohol dependence or drug abuse, history of immunologic or tumoral disease, an acute inflammatory or infectious episode in the previous month, hepatitis B, C or HIV positivity, prior transplantation, and immunotherapy or immunosuppressive treatment.
A total of I 19 patients were initially screened. Eightythree were excluded and 36 were finally eligible. Of these 36 patients, 26 presented a serum phosphate concentration higher than 5 mg/dl despite therapy with calcium-based phosphate binders at the maximum recommended daily dose, and they were switched to lanthanum carbonate (2250 mg/day) with a follow-up of 12 weeks. Three patients were withdrawn: one received a renal transplant, one due to digestive intolerance, and one patient due to an acute infectious episode. The remaining 10 patients had a serum phosphorus ::s 5 mg/dl, and were enrolled for comparative purposes as a control group, and continued receiving a calcium phosphate binder (6 subjects calcium acetate and 5 calcium carbonate). Two of these patients were withdrawn during follow-up: one received a renal transplant and the other one due to a coronary event ( Fig.  1) .
A sample size calculation was performed to check the power of the study. It was based on IL-6 as a predictor of all-cause and cardiovascular mortality in dialysis patients (16, 17) , assuming a standard deviation for IL-6 of2.6 pg/ ml (18) . To detect a 25% relative difference in the serum IL-6 concentration at the end of the study in respect to baseline for an a value of 0.05 and a~value of 0.80, a minimum of 20 individuals was necessary.
Biochemical, inflammatory parameters and FGF-23
Blood samples were drawn after an 8-h fasting period, before the midweek HD session. Serum was obtained and frozen at -80°C for analysis. Routine biochemical parameters were measured using standard methods. Serum 25-hydroxyvitamin 0 (25-VitO) was measured by radioimmunoassay, with a sensitivity < 3 nmol/L and intra-and inter-assay coefficients of variability (CV) < 8.5%. Serum high-sensitive C-reactive protein (hs-CRP) was measured by a high sensitivity particle enhanced immunoturbidimetric assay (Roche Diagnostics GmbH, Mannheim, Germany; sensitivity of 0.3 mg/I, and intraand inter-assay precision of 1.6 and 8.4, respectively). Levels ofTNF-a., IL-6 and IL-1O were measured by highsensitive immunoenzymatic ELISA method (Quantikine Human, R&D Systems, Minneapolis, USA), with a minimum detectable concentrations of 0.10 pg/ml, 0.70 pg/ml, and 12.5 pg/ml, respectively. Intra-and inter-assay CV were < 10.8%. FGF-23 concentrations were measured using a C-terminal human ELISA (Immutopics Inc., San Clemente, CA), with an intra-and inter-assay CV < 8%. All laboratory parameters were determined blinded to patients' characteristics, treatment and evolution.
Isolation of PBMe, RNA extraction and Real-Time polymerase chain reaction
PBMC were isolated from whole venous blood by density gradient centrifugation (Ficoll-Paque method). Total RNA was isolated by using TRIreagent (Sigma-Aldrich, Steinheim, Germany). The concentration and purity ofthe recovered RNAwere established by measuring ultraviolet absorbance at 260 and 280 nm, and RNA integrity was checked by agarose gel electrophoresis and ethidium bromide staining. Expression levels of TNF-a. and IL-6 were analysed by real-time quantitative RT-PCR. The primers used for quantification of targeted gene expression are as follows. For TNF-a.: forward primer, 5' -GCCACCACGCTCTTCTGT-3'; reverse primer, 5'-GGCTACGGGCTTGTCACTC-3'. For IL-6: forward primer, 5'-GTATGAACAGCGATGATGCAC-3'; reverse primer, 5' -GAAACGGAACTCCAGAAGACC-3'. For~-actin (housekeeping gene): forward primer: 5'-TCCCTGGAGAAGAGCTACGA-3'; reverse primer, 5'-ATCTGCTGGAAGGTGGACAG-3'. RT-PCR amplification was performed on an iCycler iQ Real Time PCR system (BioRad, Hercules, CA, USA) and analyzed with the iCycler software version 3.0. A three-step run protocol was used: (i) an initial hold of 9 min at 95°C to activate Taq polymerase and a fluorescence measurement to normalize the whole plate amount of fluorescein dye, (ii) an amplification and quantification cycle with 45 repeats (denaturation 20 s at 95°C, annealing 20 s at 60°C and extension 20 s at noc with a fluorescence measurement), (iii) a melting curve analysis from 65°C to 95°C to check the specificity of the amplified product. Agarose gel electrophoresis was performed to confirm that there were single-product amplifications without primer dimers. All fragments were checked for specificity by direct sequencing of both strands with an ABI PRISM 310 Genetic Analyzer using Big Dye Terminator kit v 3.1 (Applied Biosystems, Foster City, CA, USA). Expression of cytokine mRNA for each sample was expressed as an arbitrary ratio of the mRNA quantity to that of~-actin.
Statistical analysis
Data are presented as mean ± SO, except for hs-CRP, cytokines and FGF-23, which are presented as median and range. Serum concentrations of inflammatory parameters and FGF-23 were logarithmically transformed. Paired and unpaired Student's t-tests were used to compare differences intra-and inter-groups as appropriate. The chi-square test was used for differences in proportions. Correlation analysis was performed to evaluate the association between the inflammatory parameters and the other variables at baseline. Univariate and multivariate regression analyses were performed to determine the association between changes in inflammatory variables from baseline (serum concentrations and PBMC mRNA expression levels) and that of mineral metabolic parameters. A p value <0.05 was considered as significant. Data were analyzed using Statistica version 7.1 (Statsoft Inc., Tulsa, OK, USA).
RESULTS
Thirty-one patients, 23 subjects in the LaCa group and 8 in the control group, were finally evaluated. Table I shows the baseline characteristics of the study subjects. There were 16 males and 15 females, with a mean age of 63± 10 years, and an HD vintage of 16±5 months. Patients used polyacrilonitrile (66%) or polysulfone membranes (34%). Regarding vascular access, 76% had an arteriovenous fistula, whereas 24% had grafts or central dialysis catheters. Medication use was similar between groups. Most patients used antihypertensive therapy (calcium channel blockers, 61%; angiotensin converting enzyme inhibitors or angiotensin receptor blockers, 40%;~-blockers, 22%; diuretics, 19%; and a-blockers, 9%). Twenty-six patients (84%) used statins, and 92% received erythropoiesis-stimulating agents. The only difference between groups at baseline was regarding the serum phosphate concentration and the calcium-phosphate product, which were significantly higher in patients switched to LaCa. Basal serum FGF-23 concentrations was also higher in patients switched to LaCa, and the difference almost reached statistical significance 119 assessed for eligibility Excluded (n=83) Not meeting inclusion criteria 1----., or having exclusion criteria (n=81).
Refused to participate (n=2) 3 (p=0.06).
Correlation analysis among the variables at baseline demonstrated a direct and significant association between serum phosphate and FGF-23 levels (FO.70, p<O.O I), as well as between calciumphosphorus product (CaxP) and FGF-23 (FO.70, p<O.OI). Regarding inflammatory parameters, serum levels of FGF-23 showed a positive and significant association with serum concentrations of hs-CRP (r = 0.51, P < 0.01), TNF-a (r = 0.37, P < 0.05) and lL-6 (r = 0.42, P < 0.05), as well as mRNA expression levels of these inflammatory cytokines in PBMC (r = 0.47 and r = 0.56, P < 0.01, respectively). On the contrary, lL-IO did not show any relationship with FGF-23.
At the end of the study, serum phosphorus, CaxP, and serum parathyroid hormone (PTH) decreased significantly in patients switched to LaCa, without variations in the serum calcium levels (Table II) . Serum 25-VitD levels were similar to baseline values in any of the groups. However, serum FGF-23 concentrations also experienced a significant decrease, with a mean percent reduction of 10.8% in respect to baseline, as compared with a mean not-significant increase of 4.2% in patients who continued receiving calcium phosphate binders.
Regarding inflammatory variables, serum levels of hsCRP, TNF-a and IL-6 significantly decreased by 10.9% (95% confidence interval (CI), -16.9 to -4.8), 6.7% (95% CI, -14.7 to 1.2) and 8.1% (95% CI, -16.0 to -0.2), (Table II) these parameters experienced significant variations in patients treated with calcium based phosphate binders . We also evaluated the balance between pro-and anti-inflammatory forces by analysis of the evolution of the ratios of the pro-inflammatory cytokines TNF -a and IL-6 to the anti-inflammatory cytok ine IL-IO. Both at baseline and at the end of the study, there were no differences in these ratios between the groups. However, the evolution in each group was different during the study. Thus, in patients treated with LaCa the TNF-a./IL-IO and the IL-6/IL-I0 ratios experienced a median percent reduction of 15.7% and 10.9%, respectively (p<O.05 in respect to baseline), whereas these ratios increased by 3.9% and 2.3%, respectively (without differences in respect to baseline), in subjects who continued receiving calcium-based phosphate binders (p<O.05 between groups) ( Fig. 3) .
To determine whether modification of mineral metabolic variables were responsible for the changes in inflammatory parameters, we examined associations between changes in serum and mRNA expression levels of the inflammatory cytokines and variations in serum calcium, phosphorus, CaxP, PTH and FGF-23 by univariate and multivariate analysis. Univariate regression analysis showed that variations in serum phosphorus, CaxP and FGF-23 were significantly associated with changes in the serum concentrations of hsCRP, TNF-a and IL-6, as well as with variations in the mRNA expression levels ofTNF-a and IL-6 (Table III) . However, after multivariate regression analysis, changes in FGF-23 was the only independent determinant of the reduction in serum and mRNA expression levels of inflammatory parameters (Table IV) .
DISCUSSION
In the present study, administration of LaCa to HD patients with hyperphosphatemia resulted in a significant reduction of serum phosphorus, Ca x P, and iPTH. In addition, treatment with LaCa substantially lowered serum FGF-23 levels, with concomitant reductions in serum concentrations of inflammatory parameters and mRNA expression levels of inflammatory cytokines in PBMC. The decrease in the level of the inflammatory parameters was independent and significantly associated with the reductions in the concentration ofFGF-23.
Clinical studies have shown that LaCa effectively reduces serum phosphate in HD patients (19, 20) . Recently, the COLC Study reported that the addition of LaCa to HD patients with hyperphosphatemia in spite of treatment with calcium carbonate resulted in a significant reduction of serum phosphate after 16 weeks (21) . Accordingly, our work shows that in HD patients whose serum phosphate concentration was not adequatelly controlled by calciumbased phosphate binders, the switch to LaCa as monotherapy was associated with a singnificant reduction of serum phosphate, Ca x P, and iPTH levels. In addition, we observed a reduction in the serum levels of FGF-23, as well as a modulation of inflammatory parameters. ESRD is characterized by elevated levels ofFGF-23 and inflammatory markers, which are associated with adverse clinical outcomes and mortality. A recent study by Mendoza et al. (11) in a wide cohort of patients with CKD, demonstrated that elevated levels of FGF-23 are independently associated with higher concentrations of CRP, TNF-u and IL-6, and with greater odds of presenting severe inflammation. Similarly, a direct correlation was found between FGF-23 and serum concentration of these inflammatory parameters in our study. Interestingly, we also observed a direct association between FGF-23 and the mRNA expression levels of TNF-a and IL-6 in PBMC. These circulating cells play a critical role in the development and progression of atherosclerosis (22, 23) , and moreover, the increased expression of inflammatory cytokines in PBMC has been directly associated with cardiovascular events (24, 25) . This suggests that elevated FGF-23 may influence the transcription of inflammatory cytokine genes, providing an insight into the underlying cellular mechanisms of the previously described association between FGF-23 and inflammation (11), as well as between FGF-23 and adverse cardiovascular outcomes (26) . Growing interest has been paid to potential pleiotropic actions of phosphate binders. Thus, whereas calcium-based phosphate binders do not have significant effects on inflammation and FGF-23, sevelamer hydrochloride has been reported to present anti-inflammatory properties (4, 12) , along with the capacity to reduce FGF-23 (15, 27) . LaCa is also able to reduce FGF-23 both in predialysis and in HD subjects (19, 21, 28) , although its potential effects on the inflammatory profile of CKD patients has not been analyzed previously. The present study shows that serum concentrations of CRP, TNF-a and IL-6 significantly decreased after treatment with LaCa, whereas these parameters did not change in subjects who continued receiving calcium-based phosphate binders. In addition, LaCa administration was associated with a significant reduction in the mRNA expression levels of TNF-a and IL-6 in PBMC. Importantly, multivariate regression analysis demonstrated that changes in FGF-23 was the only independent determinant of the reduction of serum and mRNA expression levels of inflammatory cytokines. However, our study does not clarify the mechanisms by which reduction of FGF-23 may be associated with an anti-inflammatory action.
One explanation could be an indirect effect through vitamin D. FGF-23 is able to inhibit renal l-u-hydroxylase as well as stimulate 24-hydroxylase activity, therefore resulting in a reduction of 1,25-dihydroxyvitamin D (1,25-VitD) levels (26, 29) . Since vitamin D possesses anti-inflammatory properties (30, 31) , it is possible that reduction of FGF-23, with a parallel increase in 1,25-VitD levels may explain, at least in part, the observed modulation of inflammatory markers. Unfortunately, 1,25-VitD was not measured in our study. However, in the previous work by Mendoza et al. (11), the associations between FGF-23 and inflammatory markers did not change after adjustment for 1,25-VitD, although the vitamin D analyses were partially limited by different time of measurement.
Another factor may be a direct effect of FGF-23 on PBMC. There are no data regarding the consideration of PBMC as potential targets for FGF-23. However, a recent work by our group demonstrated the expression of FGF receptors in occluding coronary thrombi from patients with acute coronary syndrome (32) . Although we could not perform an analysis of cells within thrombi, previous studies demonstrated that monocytes are the most prominent cell type at the site of occlusion (33) . Thus, it is possible to speculate that these cells may be a target for the direct action of FGF-23, and therefore, the reduction of FGF-23 may induce a downregulation ofproinflammatory cytokine mRNA expression levels. Another relevant consideration is the recent demonstration that FGF-23 is capable of activating FGF receptors and downstream signalling cascades in cells that do not express Klotho (34, 35) . This might result in the expression of inflammatory molecules in PBMC, as well as in other organs such as liver and adipose tissue (34, 35) , an effect that would be decreased after reduction of FGF-23 concentrations.
The strengths of this study include prospective sample and uniform data adquisition, the evaluation of inflammation with determinations of serum and mRNA expression levels of the main inflammatory cytokines, and the design of the work, which was carried out under clinical practice conditions. There are, however, several weaknesses. We included patients who continued under therapy with calciumbased phosphate binders as a comparative control group, but this is not a randomized study. Secondly, this work was unblinded, although all laboratory determinations and mRNA expression levels were performed blinded to patients' characteristics, treatment and evolution, and moreover, all serum measurements and gene expression analysis were performed independently and separately. Thirdly, we could not measure 1,25-VitD, and therefore, we only can speculate about the potential role of the changes in the concentration ofthis parameter and its potential relationship with FGF-23 and the inflammatory profile. Finally, we based our determinations on single measurements of inflammatory markers that might be subjected to certain variability.
In conclusion, our study confirms the reduction ofFGF-23 concentrations after LaCa administration observed by previous works, as well as the significant association between FGF-23 and inflammation. Our study also shows that LaCa exerts antiinflammatory effects, which are significant and independently associated with the reduction ofFGF-23. In addition, our results suggest that FGF-23 may regulate inflammatory cytokine gene expression at the transcriptional level. These findings may provide partial explanation supporting the beneficial effects of LaCa on harmfull processes, such as atherosclerosis and vascular calcification (36, 37) .
